Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > New week, day, month, post, threads
View:
Post by canadafan on Mar 31, 2024 3:21pm

New week, day, month, post, threads

While we get into long threads, sometimes relevant. Sometimes subtly related to Onc..
I personally like to give some commentary, leading in to " new".
Yes, Monday starts a new day, month & even start of Q2.
in simple terms, calendar related...lots new.
however , we are lacking in any news updates.
Could Thursdays 5%+ increase be a new trend, or just well needed price recovery?
The oppotunities have been discussed sideways, backwards & forwards.
Simple deduction. Onclystics biotech needs a significant business development deal to proceed with either or both of the in waiting phase 3 trials.
The opportunities? A license/ partership deal? Countless convolutions & options.
A complete buyout? My personal preference.
Prices from one billion & upwards of tens of billions have been thrown around.
Same answer. Yes there are many comparables, that have offered much less than Onc & bought out for $5billion++
In broad strokes reality, nothing has changed. Time has moved forward. The timing of a deal is long over due.
The good news, few appreciate: The longer bracelet runs, the better.
Yes it is painful sitting & waiting. However, not happening " yet" does not in any way shape validate it won't happen.
So we wait.
Back to Thursdays price spike. Not huge volume, not a huge spike. However 5% in one day, a nice lift leading into the long weekend.
monday?
profit taking, sell off? Or further positive direction.
The news flow pragmatically supports neither.
The T.A. Numbers & price history indicate huge upside potential. As always we will see. 

I do have a challenge for all posting on here. 

See if you go a whole week without random Ad hominem attacks.
There was a time when mutiple threads carried out. Discussing Pelareorep, .M.O.A, various trial results & oppotunities.
a pleasure to read & be educated.
The name calling, open ended attacks & random distractions have become beyond obvious. fYI, check the read count.
BTW red hearings about mangemet wages, bonuses or stock options? 100% irrelevant to getting Pela to market.
THAT btw is the end goal & will be the only true way to realize the proper shareholder value.
I wish everyone a safe & healthy week.
side note, yet another acquaintance of mine.
Recent MRI repoert. Mutiple myeloma. After 6 months of chemo ( standard of  care, not Pelareorep), 
mutiple bone lesions, unchanged, one new, & one progressed.
General comments from oncologists " while various options have changed, the general outcomes with mastetic cancer,very little change in past 15 years"
Cancer my SH friends is not always a death sentence. Our lead trial Pancreatice cancer, generally is.
Should Onc get Pela into a panc phase 3 with Roche & any success, that will be considered a blockbuster.
well worth waiting for.

Comment by JohnnyYeg on Mar 31, 2024 3:50pm
!"See if you go a whole week without random Ad hominem attacks. There was a time when mutiple threads carried out. Discussing Pelareorep, .M.O.A, various trial results & oppotunities. a pleasure to read & be educated." Amen CF.... amen.
Comment by lonc17 on Mar 31, 2024 6:37pm
I found the issue that caused incomplete results from SEDI.  This is at the top of the page of the search I perform (I did not see notice it earlier when I first made the post):    ...more  
Comment by Azzak34 on Mar 31, 2024 6:54pm
I'll say it again, spend a little more time on your "research"!! You're making yourself look a silly Billy. 
Comment by Hydroqc on Mar 31, 2024 11:40pm
You deserve a piece of robot Ionc17 for confessing your mistake after refining your research. Now if you want to complete the robot, you should read again some of your other post and refine your search on them too. I don't think you are a basher for the purpuse of bashing, but just a frustrated investor. A guy that putted too much money in a INTDF homerun. I never really considered ONC as a ...more  
Comment by Azzak34 on Apr 01, 2024 4:01pm
We're getting there John. We may not get the buyout we're all banking on this year but a good run-up in SP, somewhere in the $5-7 range is highly likely. I think people will have a decision on when to take a decent profit and when to hang on and see if the big payday comes. I have my own number but I'm sure others will vary.  Google work and research on OVs in general and you' ...more  
Comment by JohnnyYeg on Apr 01, 2024 4:13pm
I'm trying to buddy. One thing that frustrates me are the start of the year reports from EY, etc., that state this is the year Big Pharma is focusing on mid size bolt on acquisitions of the 10+ billion dollar range. Exact same predictions for the past 4 or 5 years. I mean geez - change more than the year for each year's report!
Comment by Azzak34 on Apr 01, 2024 4:22pm
I hear ya. There has only ever been 1 OV approved for commercial use so it's not quite like for like across the board. We have a harder path to market because it's a fairly new "idea" than others who are a little more "mainstream" therapies.  Honestly though there is so much work being done on OVs and immunotherapies so we're well placed when BP realizes the ...more  
Comment by Noteable on Apr 01, 2024 6:06pm
In 2004, a nonpathogenic enteric cytopathic human orphan virus (Rigvir) was approved in Latvia for the treatment of melanoma, which was the first OV to be approved for cancer treatment worldwide. A genetically modified recombinant human adenovirus type 5, Oncorine or H101, was approved for marketing in China in 2005. In 2015, the Food and Drug Administration (FDA) of USA approved T-vec ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities